{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T12:25:03Z","timestamp":1777897503762,"version":"3.51.4"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Funct Integr Genomics"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s10142-026-01871-7","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:30:47Z","timestamp":1777595447000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of MUC3A P258S mutation with advanced phase CML structural and in silico insights"],"prefix":"10.1007","volume":"26","author":[{"given":"Sameen","family":"Shahid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zafar","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Abbas","family":"Khokhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0135-2991","authenticated-orcid":false,"given":"Muhammad Farooq","family":"Sabar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"issue":"2","key":"1871_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.5306\/wjco.v12.i2.69","volume":"12","author":"MM Sampaio","year":"2021","unstructured":"Sampaio MM et al (2021) Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: a literature review. World J Clin Oncol 12(2):69","journal-title":"World J Clin Oncol"},{"issue":"1","key":"1871_CR2","first-page":"44","volume":"14","author":"J Cortes","year":"2021","unstructured":"Cortes J, Lang FJJoH, Oncology (2021) Third-line therapy chronic myeloid leukemia: Curr status future Dir 14(1):44","journal-title":"Third-line therapy chronic myeloid leukemia: Curr status future Dir"},{"issue":"5","key":"1871_CR3","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1182\/bloodadvances.2020002973","volume":"5","author":"A Nasser","year":"2021","unstructured":"Nasser A et al (2021) Molecular response to imatinib in patients with chronic myeloid leukemia in Tanzania. Blood Adv 5(5):1403\u20131411","journal-title":"Blood Adv"},{"key":"1871_CR4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.0220","author":"E Jabbour","year":"2025","unstructured":"Jabbour E, Kantarjian HJJ (2025) Chronic myeloid leukemia: a review. JAMA. https:\/\/doi.org\/10.1001\/jama.2025.0220","journal-title":"JAMA"},{"issue":"Supplement 1","key":"1871_CR5","doi-asserted-by":"publisher","first-page":"7429","DOI":"10.1182\/blood-2023-185547","volume":"142","author":"S Shahid","year":"2023","unstructured":"Shahid S et al (2023) Discovery of Mutated MUC3A Gene As a Novel Transcription Factor Exclusively Associated with Accelerated Phase Chronic Myeloid Leukemia: Hunt for Common Biomarker of Fatal CML Progression. Blood 142(Supplement 1):7429\u20137429","journal-title":"Blood"},{"issue":"11","key":"1871_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/biology10111182","volume":"10","author":"Z Iqbal","year":"2021","unstructured":"Iqbal Z et al (2021) Integrated genomic analysis identifies ANKRD36 gene as a novel and common biomarker of disease progression in chronic myeloid leukemia. Biology 10(11):1182","journal-title":"Biology"},{"key":"1871_CR7","unstructured":"Xu J, JJATi H, Qiu, Medicine (2024) Mucin 3A\u2019s Promotion of the Proliferation and Migration of Gastric Cancer Cells Through Activation of the mTOR Pathway. : p. AT9871-AT9871"},{"key":"1871_CR8","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s10555-018-09775-0","volume":"38","author":"R Bhatia","year":"2019","unstructured":"Bhatia R et al (2019) Cancer-associated mucins: role in immune modulation and metastasis. Cancer Metastasis Rev 38:223\u2013236","journal-title":"Cancer Metastasis Rev"},{"issue":"6","key":"1871_CR9","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872\u2013884","journal-title":"Blood"},{"issue":"6","key":"1871_CR10","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1002\/cncr.21756","volume":"106","author":"JE Cortes","year":"2006","unstructured":"Cortes JE et al (2006) Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cancer 106(6):1306\u20131315","journal-title":"Cancer"},{"issue":"4","key":"1871_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040798","volume":"13","author":"M Suttorp","year":"2021","unstructured":"Suttorp M et al (2021) Definition, epidemiology, pathophysiology, and essential criteria for diagnosis of pediatric chronic myeloid leukemia. Cancers 13(4):798","journal-title":"Cancers"},{"issue":"2","key":"1871_CR12","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1158\/1078-0432.CCR-13-1988","volume":"20","author":"F-X Mahon","year":"2014","unstructured":"Mahon F-X, Etienne GJCCR (2014) Deep molecular response in chronic myeloid leukemia: the new goal of therapy?. Clin Cancer Res 20(2):310\u2013322","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1871_CR13","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1038\/leu.2012.104","volume":"26","author":"N Cross","year":"2012","unstructured":"Cross N et al (2012) Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 26(10):2172\u20132175","journal-title":"Leukemia"},{"issue":"3","key":"1871_CR14","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.scijus.2015.01.005","volume":"55","author":"SC Ip","year":"2015","unstructured":"Ip SC et al (2015) An evaluation of the performance of five extraction methods: chelex\u00ae 100, QIAamp\u00ae DNA blood mini kit, QIAamp\u00ae DNA investigator kit, QIAsymphony\u00ae DNA Investigator\u00ae kit and DNA IQ\u2122. Sci Justice 55(3):200\u2013208","journal-title":"Sci Justice"},{"key":"1871_CR15","unstructured":"Absar M et al (2020) Whole exome sequencing identifies a novel FANCD2 gene splice site mutation associated with disease progression in chronic myeloid leukemia: Implication in targeted therapy of advanced phase CML. 33(3):1419\u20131426"},{"issue":"7","key":"1871_CR16","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/gim.2015.148","volume":"18","author":"K Retterer","year":"2016","unstructured":"Retterer K et al (2016) Clinical application of whole-exome sequencing across clinical indications. Genet Med 18(7):696\u2013704","journal-title":"Genet Med"},{"issue":"1","key":"1871_CR17","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1172\/JCI78473","volume":"125","author":"S AlAsiri","year":"2015","unstructured":"AlAsiri S et al (2015) Exome sequencing reveals MCM8 mutation underlies ovarian failure and chromosomal instability. J Clin Invest 125(1):258\u2013262","journal-title":"J Clin Invest"},{"issue":"4","key":"1871_CR18","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2353\/jmoldx.2010.090188","volume":"12","author":"AC Tsiatis","year":"2010","unstructured":"Tsiatis AC et al (2010) Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. The Journal of molecular diagnostics\u202f: JMD 12(4):425\u2013432","journal-title":"The Journal of molecular diagnostics : JMD"},{"key":"1871_CR19","unstructured":"SPSS IJSI, Chicago IL (2012) USA, IBM SPSS statistics 20.0."},{"issue":"9","key":"1871_CR20","first-page":"44","volume":"7","author":"EU Oti","year":"2021","unstructured":"Oti EU, Olusola MO, A.J.I.J.o.A P (2021) Stat Anal median test Mann-Whitney U test 7(9):44\u201351","journal-title":"Stat Anal median test Mann-Whitney U test"},{"key":"1871_CR21","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1385\/1-59259-890-0:571","volume-title":"The proteomics protocols handbook","author":"E Gasteiger","year":"2005","unstructured":"Gasteiger E (2005) Protein identification and analysis tools on the ExPASy server. The proteomics protocols handbook. pp 571\u2013607"},{"issue":"D1","key":"1871_CR22","doi-asserted-by":"publisher","first-page":"D447","DOI":"10.1093\/nar\/gku1003","volume":"43","author":"D Szklarczyk","year":"2015","unstructured":"Szklarczyk D et al (2015) STRING v10: protein\u2013protein interaction networks, integrated over the tree of life. Nucleic Acids Res 43(D1):D447\u2013D452","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"1871_CR23","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1093\/bioinformatics\/btt691","volume":"30","author":"DE Pires","year":"2014","unstructured":"Pires DE, Ascher DB, Blundell TL (2014) Mcsm: predicting the effects of mutations in proteins using graph-based signatures. Bioinformatics 30(3):335\u2013342","journal-title":"Bioinformatics"},{"issue":"suppl2","key":"1871_CR24","doi-asserted-by":"publisher","first-page":"W215","DOI":"10.1093\/nar\/gkr363","volume":"39","author":"CL Worth","year":"2011","unstructured":"Worth CL, Preissner R, Blundell TL (2011) SDM\u2014a server for predicting effects of mutations on protein stability and malfunction. Nucleic Acids Res 39(suppl2):W215\u2013W222","journal-title":"Nucleic Acids Res"},{"issue":"W1","key":"1871_CR25","doi-asserted-by":"publisher","first-page":"W314","DOI":"10.1093\/nar\/gku411","volume":"42","author":"DE Pires","year":"2014","unstructured":"Pires DE, Ascher DB, Blundell TL (2014) Duet: a server for predicting effects of mutations on protein stability using an integrated computational approach. Nucleic Acids Res 42(W1):W314\u2013W319","journal-title":"Nucleic Acids Res"},{"issue":"suppl2","key":"1871_CR26","doi-asserted-by":"publisher","first-page":"W306","DOI":"10.1093\/nar\/gki375","volume":"33","author":"E Capriotti","year":"2005","unstructured":"Capriotti E, Fariselli P, Casadio R (2005) I-Mutant2.0: predicting stability changes upon mutation from the protein sequence or structure. Nucleic Acids Res 33(suppl2):W306\u2013W310","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"1871_CR27","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/humu.21242","volume":"31","author":"S Khan","year":"2010","unstructured":"Khan S, Vihinen M (2010) Performance of protein stability predictors. Hum Mutat 31(6):675\u2013684","journal-title":"Hum Mutat"},{"issue":"W1","key":"1871_CR28","doi-asserted-by":"publisher","first-page":"W452","DOI":"10.1093\/nar\/gks539","volume":"40","author":"N-L Sim","year":"2012","unstructured":"Sim N-L et al (2012) SIFT web server: predicting effects of amino acid substitutions on proteins. Nucleic Acids Res 40(W1):W452\u2013W457","journal-title":"Nucleic Acids Res"},{"issue":"W1","key":"1871_CR29","doi-asserted-by":"publisher","first-page":"W247","DOI":"10.1093\/nar\/gkx369","volume":"45","author":"E Capriotti","year":"2017","unstructured":"Capriotti E, Fariselli P (2017) PhD-SNPg: a webserver and lightweight tool for scoring single nucleotide variants. Nucleic Acids Res 45(W1):W247\u2013W252","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"1871_CR30","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/bioinformatics\/16.4.404","volume":"16","author":"LJ McGuffin","year":"2000","unstructured":"McGuffin LJ, Bryson K, Jones DT (2000) The PSIPRED protein structure prediction server. Bioinformatics 16(4):404\u2013405","journal-title":"Bioinformatics"},{"issue":"8016","key":"1871_CR31","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","volume":"630","author":"J Abramson","year":"2024","unstructured":"Abramson J et al (2024) Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 630(8016):493\u2013500","journal-title":"Nature"},{"key":"1871_CR32","unstructured":"Jejurikar BL, Rohane SH (2021) Drug designing in discovery studio."},{"issue":"2","key":"1871_CR33","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s10930-020-09953-6","volume":"40","author":"V Dalal","year":"2021","unstructured":"Dalal V et al (2021) Structure-Based Identification of Potential Drugs Against FmtA of Staphylococcus aureus: Virtual Screening, Molecular Dynamics, MM-GBSA, and QM\/MM. Protein J 40(2):148\u2013165","journal-title":"Protein J"},{"key":"1871_CR34","doi-asserted-by":"crossref","unstructured":"Knox C et al (2024) DrugBank 6.0: the DrugBank knowledgebase for 2024. 52(D1): pp. D1265-D1275","DOI":"10.1093\/nar\/gkad976"},{"key":"1871_CR35","doi-asserted-by":"crossref","unstructured":"Gewirtz DJ (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. 57(7):727\u2013741","DOI":"10.1016\/S0006-2952(98)00307-4"},{"key":"1871_CR36","doi-asserted-by":"crossref","unstructured":"Ascierto PA et al (2021) 5-year outcomes with cobimetinib plus vemurafenib in BRAF V600 mutation\u2013positive advanced melanoma: extended follow-up of the coBRIM study. 27(19):5225\u20135235","DOI":"10.1158\/1078-0432.CCR-21-0809"},{"key":"1871_CR37","doi-asserted-by":"crossref","unstructured":"Eleutherakis-Papaiakovou E et al (2020) Efficacy of panobinostat for the treatment of multiple myeloma. 2020(1):7131802","DOI":"10.1155\/2020\/7131802"},{"key":"1871_CR38","doi-asserted-by":"crossref","unstructured":"Burness CBJD (2015) Sonidegib: first global approval. 75(13):1559\u20131566","DOI":"10.1007\/s40265-015-0458-y"},{"key":"1871_CR39","doi-asserted-by":"crossref","unstructured":"Soria J-C et al (2018) Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer. 378(2):113\u2013125","DOI":"10.1056\/NEJMoa1713137"},{"key":"1871_CR40","doi-asserted-by":"crossref","unstructured":"Yang X et al (2025) Comparison of the effectiveness of alectinib versus crizotinib followed by alectinib in patients with ALK-positive advanced non-small-cell lung cancer in real-world setting and in the ALEX study. 14(4):1158","DOI":"10.21037\/tlcr-24-898"},{"key":"1871_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1291920","volume":"14","author":"Q Cao","year":"2023","unstructured":"Cao Q et al (2023) Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: a literature review. Front Pharmacol 14:1291920","journal-title":"Front Pharmacol"},{"key":"1871_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.668162","volume":"11","author":"HA Abbas","year":"2021","unstructured":"Abbas HA, Wierda W (2021) Acalabrutinib: a selective Bruton tyrosine kinase inhibitor for the treatment of B-cell malignancies. Front Oncol 11:668162","journal-title":"Front Oncol"},{"issue":"6","key":"1871_CR43","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/s41571-018-0019-x","volume":"15","author":"PJNRCO Sidaway","year":"2018","unstructured":"Sidaway PJNRCO (2018) Encorafenib\u2014a new agent for advanced-stage disease. Nat Rev Clin Oncol 15(6):344\u2013345","journal-title":"Nat Rev Clin Oncol"},{"key":"1871_CR44","doi-asserted-by":"publisher","DOI":"10.1042\/BST20253091","author":"P Ghosh","year":"2025","unstructured":"Ghosh P, Pecora I, Park MJBST (2025) Mechanistic insights into MET exon 14 skipping mutations and their role in tumor progression.. Biochem Soc Trans. https:\/\/doi.org\/10.1042\/BST20253091","journal-title":"Biochem Soc Trans"},{"issue":"8","key":"1871_CR45","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","volume":"381","author":"A Chari","year":"2019","unstructured":"Chari A et al (2019) Oral selinexor\u2013dexamethasone for triple-class refractory multiple myeloma. N Engl J Med 381(8):727\u2013738","journal-title":"N Engl J Med"},{"issue":"2","key":"1871_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/ph12020069","volume":"12","author":"DA Rodrigues","year":"2019","unstructured":"Rodrigues DA, Sagrillo FS, Fraga CAJP (2019) Duvelisib: a 2018 novel FDA-approved small molecule inhibiting phosphoinositide 3-kinases. Pharmaceuticals 12(2):69","journal-title":"Pharmaceuticals"},{"issue":"20","key":"1871_CR47","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.1158\/1078-0432.CCR-19-0365","volume":"25","author":"KJ Norsworthy","year":"2019","unstructured":"Norsworthy KJ et al (2019) FDA approval summary: glasdegib for newly diagnosed acute myeloid leukemia. Clin Cancer Res 25(20):6021\u20136025","journal-title":"Clin Cancer Res"},{"issue":"21","key":"1871_CR48","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","volume":"383","author":"AT Shaw","year":"2020","unstructured":"Shaw AT et al (2020) First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med 383(21):2018\u20132029","journal-title":"N Engl J Med"},{"issue":"18","key":"1871_CR49","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE et al (2019) Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med 381(18):1728\u20131740","journal-title":"N Engl J Med"},{"key":"1871_CR50","doi-asserted-by":"crossref","unstructured":"Camidge DR et al (2021) Brigatinib versus crizotinib in ALK inhibitor\u2013naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial. 16(12):2091\u20132108","DOI":"10.1016\/j.jtho.2021.07.035"},{"issue":"3","key":"1871_CR51","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41375-023-01829-9","volume":"37","author":"A Hochhaus","year":"2023","unstructured":"Hochhaus A et al (2023) Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia 37(3):617\u2013626","journal-title":"Leukemia"},{"issue":"6","key":"1871_CR52","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK et al (2020) Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 21(6):796\u2013807","journal-title":"Lancet Oncol"},{"issue":"8","key":"1871_CR53","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon A et al (2018) Efficacy of larotrectinib in TRK fusion\u2013positive cancers in adults and children. N Engl J Med 378(8):731\u2013739","journal-title":"N Engl J Med"},{"key":"1871_CR54","unstructured":"Lucas MD (n.d.) Pour Le Diplome D\u2019Etat De Docteur En Pharmacie"},{"issue":"1","key":"1871_CR55","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2300696","volume":"389","author":"AR Mato","year":"2023","unstructured":"Mato AR et al (2023) Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia. N Engl J Med 389(1):33\u201344","journal-title":"N Engl J Med"},{"issue":"20","key":"1871_CR56","doi-asserted-by":"publisher","first-page":"9833","DOI":"10.1080\/07391102.2021.1936179","volume":"40","author":"R Kumari","year":"2022","unstructured":"Kumari R, Dalal V (2022) Identification of potential inhibitors for LLM of Staphylococcus aureus: structure-based pharmacophore modeling, molecular dynamics, and binding free energy studies. J Biomol Struct Dyn 40(20):9833\u20139847","journal-title":"J Biomol Struct Dyn"},{"issue":"5","key":"1871_CR57","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1002\/prot.26303","volume":"90","author":"B White","year":"2022","unstructured":"White B et al (2022) Crystal structure of a human MUC16 SEA domain reveals insight into the nature of the CA125 tumor marker. Proteins 90(5):1210\u20131218","journal-title":"Proteins"},{"issue":"16","key":"1871_CR58","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/jcc.20291","volume":"26","author":"D Van Der Spoel","year":"2005","unstructured":"Van Der Spoel D et al (2005) GROMACS: fast, flexible, and free. J Comput Chem 26(16):1701\u20131718","journal-title":"J Comput Chem"},{"key":"1871_CR59","doi-asserted-by":"publisher","first-page":"7429","DOI":"10.1182\/blood-2023-185547","volume":"142","author":"S Shahid","year":"2023","unstructured":"Shahid S et al (2023) Discovery of mutated MUC3A gene as a novel transcription factor exclusively associated with accelerated phase chronic myeloid leukemia: hunt for common biomarker of fatal CML progression. Blood 142:7429","journal-title":"Blood"},{"key":"1871_CR60","doi-asserted-by":"publisher","DOI":"10.5958\/0974-4150.2021.00014.6","author":"SS Pawar","year":"2021","unstructured":"Pawar SS, Rohane SH (2021) Review on discovery studio: an important tool for molecular docking. Asian Journal Of Research in Chemistry. https:\/\/doi.org\/10.5958\/0974-4150.2021.00014.6","journal-title":"Asian Journal Of Research in Chemistry"},{"key":"1871_CR61","first-page":"243","volume-title":"Chemical biology: methods and protocols","author":"S Dallakyan","year":"2014","unstructured":"Dallakyan S, Olson AJ (2014) Small-molecule library screening by docking with PyRx. Chemical biology: methods and protocols. Springer, pp 243\u2013250"},{"key":"1871_CR62","doi-asserted-by":"crossref","unstructured":"Okeke I (2022) Molecular Docking and Analysis of some Ligands on Var2csA Target.","DOI":"10.21203\/rs.3.rs-2070110\/v1"},{"issue":"5","key":"1871_CR63","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/pro.2449","volume":"23","author":"CN Pace","year":"2014","unstructured":"Pace CN et al (2014) Contribution of hydrogen bonds to protein stability. Protein Sci 23(5):652\u2013661","journal-title":"Protein Sci"},{"key":"1871_CR64","doi-asserted-by":"publisher","first-page":"132476","DOI":"10.1016\/j.molstruc.2022.132476","volume":"1255","author":"R Kumari","year":"2022","unstructured":"Kumari R et al (2022) Structural-based virtual screening and identification of novel potent antimicrobial compounds against YsxC of Staphylococcus aureus. J Mol Struct 1255:132476","journal-title":"J Mol Struct"},{"issue":"1","key":"1871_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02027-6","volume":"23","author":"M Zuckermann","year":"2024","unstructured":"Zuckermann M et al (2024) Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy. Mol Cancer 23(1):123","journal-title":"Mol Cancer"},{"issue":"3","key":"1871_CR66","doi-asserted-by":"publisher","first-page":"e232","DOI":"10.1016\/j.cllc.2024.12.004","volume":"26","author":"M Takeda","year":"2025","unstructured":"Takeda M et al (2025) A phase II, open label, single-arm study on the efficacy of cabozantinib in patients with advanced\/metastatic nonsmall cell lung cancer harboring MET exon 14 alterations who developed acquired resistance to tepotinib or capmatinib (CAPTURE trial). Clin Lung Cancer 26(3):e232\u2013e235","journal-title":"Clin Lung Cancer"},{"issue":"Abstracts","key":"1871_CR67","first-page":"A4908","volume":"211","author":"H Nieves","year":"2025","unstructured":"Nieves H, Rodriguez WJAJoR, Medicine CC (2025) Mol Profiling: Genomic Guided Therapy Lung Adenocarcinoma 211(Abstracts):A4908\u2013A4908","journal-title":"Mol Profiling: Genomic Guided Therapy Lung Adenocarcinoma"},{"issue":"1","key":"1871_CR68","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10867-025-09683-9","volume":"51","author":"T Joshi","year":"2025","unstructured":"Joshi T et al (2025) In-silico evaluation of Azadirachta indica-derived Daucosterol against key viral proteins of Ebolavirus using ML and MD simulations approach. J Biol Phys 51(1):17","journal-title":"J Biol Phys"},{"issue":"1","key":"1871_CR69","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1007\/s12672-025-03182-y","volume":"16","author":"S Balaji","year":"2025","unstructured":"Balaji S et al (2025) Hispidulin: a potential alternative to vorinostat against HDAC1 for acute myeloid leukemia. Discover Oncol 16(1):1389","journal-title":"Discover Oncol"},{"key":"1871_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/cimb47060406","author":"C Chen","year":"2025","unstructured":"Chen C et al (2025) The role of mucins in cancer and cancer progression: a comprehensive review. Curr Issues Mol Biol. https:\/\/doi.org\/10.3390\/cimb47060406","journal-title":"Curr Issues Mol Biol"}],"container-title":["Functional & Integrative Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10142-026-01871-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10142-026-01871-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10142-026-01871-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T09:01:35Z","timestamp":1777626095000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10142-026-01871-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1871"],"URL":"https:\/\/doi.org\/10.1007\/s10142-026-01871-7","relation":{},"ISSN":["1438-793X","1438-7948"],"issn-type":[{"value":"1438-793X","type":"print"},{"value":"1438-7948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"assertion":[{"value":"9 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For this study was obtained from the Ethical Review Board of Jinnah Hospital, Lahore (Ref No: 256\/26\/05\/2022\/S1 ERB), and the Ethical Review Board of the University of the Punjab, Lahore (Ref No: 65\/FIMS). Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"89"}}